1 / 6

Includes adults >65 years old

Geriatric Pharmacology: Relevance Clarissa Zaoirov (2009). Includes adults >65 years old. Fastest growing population in US and in the majority of developed nations.

rudolf
Download Presentation

Includes adults >65 years old

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Geriatric Pharmacology: Relevance Clarissa Zaoirov (2009) Includes adults >65 years old • Fastest growing population in US and in the majority of developed nations. • 20% of hospitalizations for those >65 are due to medications they’re taking = Adverse Drug Events/Interactions are very common in the elderly.

  2. What is different about geriatric pharmacotherapy? • Absorption – Not usually significantly altered with age. Reduced motility and gastric emptying = constipation • Distribution – Change in total body composition, vascular changes, lower albumin production (not always) • Metabolism – Reduced hepatic blood flow & mass, low CYP-450, slow biotransformation (Phase I metabolic pathways) • Excretion = Renal blood flow by age 80, can be reduced by as much as ½. Reduction in tubular function & size.

  3. Pharmacodynamic Changes: • Disturbed homeostatic mechanisms: • - Reduced compensatory tachycardia, baroreceptor and vasomotor response. • - Poor thermoregulatory mechanisms • - Cardiac Beta receptor sensitivity reduced • - Hepatic Beta receptor sensitivity increased • - Greater sensitivity to medications affecting the CNS (benzodiazepines and opioids) • - Pre-existing depletion of dopamine = Parkinsonism when using anti-psychotic medications.

  4. Total Result: • These age-related changes result in greater therapeutic effect and increased risk of accumulation & toxicity. (Longer ½ life) • Complicated by alterations in metabolism, distribution and clearance. • Example: Benzodiazepines may cause more sedation and poorer psychomotor performance in older adults. Likely cause: reduced clearance of the drug and resultant higher plasma levels, wider volume of distribution of lipophylic drug and active metabolites.

  5. Other factors that complicate pharmacotherapy: • Polypharmacy including naturaceuticals. (Ginko biloba) • Non-Compliance Issues • Drug-Disease Interactions • - Anticholinergics Benign. Prostatic Hypertrophy (BPH), constipation, dementia • Antiarrhythmics (Type 1A) CHF (systolic dysfunction) • Amphetamines Hypertension (HTN), insomnia • Aspirin Peptic Ulcer disease (PUD) • Atypical antipsychotics DM (Diabetes Mellitus) • Barbiturates Depression • Benzodiazepines COPD,dementia, falls • Beta-blockers COPD, DM, syncope • CCB 1st generation CHF (systolic dysfunction) • Chlorpromazine Postural hypotension, seizures • Clozapine Seizures • Corticosteroids DM, PUD, COPD • Decongestants Insomnia

  6. Recommendations: • Start low and advance dosage slowly. Avoid the prescription cascade! • Cockcroft-Gualt Formula (Creatinine Clearance) : • Beers Criteria or MAI * • ANY new symptom or disease in an elderly patient should be treated as Adverse Drug Event unless proven otherwise. (i.e.. Dementia) Constantly review medications for appropriateness.

More Related